搜索结果: 16-30 共查到“医学 SARS-COV-2”相关记录48条 . 查询时间(0.147 秒)
上海交通大学系统生物医学研究院陶生策团队合作开发SARS-CoV-2蛋白质组芯片全局性分析新冠病人血清IgG&IgM应答(图)
上海交通大学系统生物医学研究院 陶生策 SARS-CoV-2 蛋白质组 芯片 全局性分析 新冠 血清IgG&IgM应答
2020/8/28
COVID-19的全球大流行到目前为止已经造成了一千多万人的感染,五十多万的死亡病例。针对新冠病毒的抗体,特别是IgG和IgM进行检测,有助于新冠病毒感染的诊断,是核酸检测的有力补充。目前已鉴定的抗原主要有核衣壳蛋白(N蛋白)和刺突糖蛋白(S蛋白),对于新冠病毒其它蛋白的抗原性的鉴定仍为空白。另外,探索病人体内的抗体响应强度与年龄、性别、疾病的进展和严重程度等是否有相关性,将有助于我们进一步理解病...
在中国,由于采取了强有力的措施,COVID-19的流行已暂时得到控制,而除了一些进口病例外,新病例很少。基于PCR的检测结果结合临床症状已被广泛用于COVID-19的检测和确证,但是在中国无症状或亚临床SARS-CoV-2感染的患病率仍然未知。2020年7月20日,华中科技大学,南方医科大学及广州医科大学等多单位合作,钟南山,韩光,胡德胜及何建行等人在Cell Research 在线发表题为“Se...
美国研究首次证实:SARS-CoV-2不能通过蚊子传播
美国 首次证实 SARS-CoV-2 蚊子传播
2020/7/20
美国堪萨斯州立大学一项研究证实,新冠病毒不能通过蚊子传播给人类。研究人员17日在《科学报告》杂志上发表论文称,新研究首次提供了确凿的实验数据,支持了世界卫生组织(WHO)关于蚊子不能传播新冠病毒的论断。
选择合适的标本类型进行SARS-CoV-2检测,为新型冠状病毒肺炎(COVID-19)的早期诊断提供依据。 方法:采集咽拭子核酸检测阳性的4名COVID-19患者的鼻拭子、粪便、尿液、血液(分离血清)标本,用实时荧光RT-PCR进行SARS-CoV-2核酸检测,用化学发光法检测患者血清IgM和IgG。
A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
Preventive medicine SARS-CoV-2 Viral infection
2020/6/11
An outbreak of the coronavirus disease 2019 (COVID-19)1–3, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4 spread globally. Countermeasures are needed to treat and prevent ...
Structural basis for RNA replication by the SARS-CoV-2 polymerase
2019-nCoV SARS-CoV-2 COVID-19 remdesivir favipiravir polymerase RdRP virus nsp12 nsp8
2020/6/11
Nucleotide analog inhibitors, including broad-spectrum remdesivir and favipiravir, have shown promise in in vitro assays and some clinical studies for COVID-19 treatment, this despite an incomplete me...
Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2
SARS-CoV-2 human ACE2 transgenic mouse COVID-19 pneumonia
2020/6/11
COVID-19 has spread worldwide since 2019 and is now a severe threat to public health. We previously identified the causative agent as a novel SARS-related coronavirus (SARS-CoV-2) that uses human angi...
Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture
Novel coronavirus alkaloid broad-spectrum antiviral 2019-nCoV SARS-CoV-2
2020/6/11
The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined...
Key Residues of the Receptor Binding Motif in the Spike Protein of SARS-CoV-2 That Interact With ACE2 and Neutralizing Antibodies
SARS-CoV-2 cross-neutralizing antibody receptor binding motif spike protein substitution mutation
2020/6/11
Coronavirus disease 2019 (COVID-19), caused by the novel human coronavirus SARS-CoV-2, is currently a major threat to public health worldwide. The viral spike protein binds the host receptor angiotens...
Structural Basis for the Inhibition of SARS-CoV-2 Main Protease by Antineoplastic Drug Carmofur
SARS-CoV-2 cross-neutralizing antibody receptor binding motif spike protein substitution mutation
2020/6/11
The antineoplastic drug carmofur is shown to inhibit the SARS-CoV-2 main protease (Mpro). Here, the X-ray crystal structure of Mpro in complex with carmofur reveals that the carbonyl reactive group of...
南京中医药大学柳红教授团队研发出新型抗SARS-CoV-2病毒候选药物,研究成果在Science发表(图)
南京中医药大学 柳红教授 新型抗SARS-CoV-2病毒 候选药物 研究成果 Science发表
2020/4/30
近日,我校新中药学院院长柳红教授和中国科学院上海药物所蒋华良院士研究团队与上海科技大学、中国科学院武汉病毒所研究团队合作,在抗新型冠状病毒药物研究中取得重要进展,发现一类结构新颖、高效、安全的靶向SARS-CoV-2病毒候选药物。该研究成果于4月22日在Science在线发表,我校在读博士研究生李建是作者之一。
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
The anti-influenza virus drug arbidol efficient inhibitor SARS-CoV-2 in vitro
2020/6/11
Since December 2019, a novel disease COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread to over 200 countries and infected over 1.50 million people includin...
截止2020年4月22日,由新型冠状病毒(SARS-CoV-2)感染引起的肺炎(COVID-19)全球确诊病例接近260万,感染死亡人数已超过17万,已发展为全球性的大流行病,且目前尚无特效的抗病毒药物和疫苗用于COVID-19的治疗。
As of March 10, 2020, the 2019 novel coronavirus (SARS-CoV-2) has been responsible for more than 110,000 infections and 4000 deaths worldwide, but data regarding the epidemiologic characteristics and ...
近日,中国科学院上海药物研究所柳红/许叶春/蒋华良团队联合上海科技大学杨海涛/饶子和团队和中国科学院武汉病毒所张磊砢/肖庚富团队通力合作,在抗新型冠状病毒药物研究中取得重要进展,发现一类结构新颖、高效、安全的抗SARS-CoV-2病毒候选药物。该研究成果于3月28日发表在生物预印本网站bioRxiv上,并于4月22日在Science上在线发表。截止目前,由新型冠状病毒(SARS-CoV-2)感染引...